Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes

NCT03011021 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the safety of combining umbilical cord blood regulatory T cells with the drug liraglutide in adults with type 1 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2017-01 · est. completion 2025-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03011021 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo expanded umbilical cord blood regulatory T cells adjunct with Liraglutide on autoimmune diabetes.

Treatments tested

Liraglutide Drug

Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
UCB-Treg Biologic

Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline
Insulin Drug

Receive insulin following clinician's instruction.

Main thing measured	Adverse effects
Sponsor	Second Xiangya Hospital of Central South University
Conditions studied	Type1 Diabetes Mellitus, Autoimmune Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03011021 ↗